

The New England Journal of Medicine

©Copyright, 1996, by the Massachusetts Medical Society

Volume 334

JANUARY 4, 1996

Number 1

CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER

WILLIAM P. MCGUIRE, M.D., WILLIAM J. HOSKINS, M.D., MARK F. BRADY, B.S., PAUL R. KUCERA, M.D.,
EDWARD E. PARTRIDGE, M.D., KATHERINE Y. LOOK, M.D., DANIEL L. CLARKE-PEARSON, M.D.,
AND MARTIN DAVIDSON, M.D.

Abstract Background. Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide long-term control of disease in few patients, however. We compared two combinations, cisplatin and cyclophosphamide and cisplatin and paclitaxel, in women with ovarian cancer.

Methods. We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive cisplatin (75 mg per square meter of body-surface area) with either cyclophosphamide (750 mg per square meter) or paclitaxel (135 mg per square meter over a period of 24 hours).

Results. Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently

in the cisplatin-paclitaxel group. Among 216 women with measurable disease, 73 percent in the cisplatin-paclitaxel group responded to therapy, as compared with 60 percent in the cisplatin-cyclophosphamide group ($P=0.01$). The frequency of surgically verified complete response was similar in the two groups. Progression-free survival was significantly longer ($P<0.001$) in the cisplatin-paclitaxel group than in the cisplatin-cyclophosphamide group (median, 18 vs. 13 months). Survival was also significantly longer ($P<0.001$) in the cisplatin-paclitaxel group (median, 38 vs. 24 months).

Conclusions. Incorporating paclitaxel into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer. (N Engl J Med 1996;334:1-6.)

©1996, Massachusetts Medical Society.

A STANDARD therapy for women with advanced epithelial ovarian cancer in the United States is an alkylating agent plus cisplatin. Cisplatin-based combination therapy has been found to be more effective than alkylating agents alone¹ or combinations without cisplatin,^{2,3} when measured by clinical response rates and progression-free intervals. However, the evidence of benefit in overall survival is less compelling.⁴ When alkylating agents or combinations not containing plati-

num were used in advanced ovarian cancer, the anticipated average response rate was 40 to 50 percent (10 to 20 percent complete pathological response), with a median survival of 12 to 15 months. In women treated with cisplatin combinations as primary therapy, the response rates are 60 to 80 percent, with complete responses being most common in women who have had adequate surgical therapy.⁵

The only large prospective, randomized study comparing cisplatin with a cisplatin-containing combination in advanced ovarian cancer suggested that cisplatin by itself is as effective as platinum-based combinations⁶ and is less toxic and less likely to lead to secondary tumors. Nevertheless, an overview of randomized therapeutic trials suggested that platinum-containing combinations are better than cisplatin alone.⁷ In patients with advanced ovarian cancer, a combination of cisplatin and cyclophosphamide is now standard treatment. Unfortunately, long-term disease control with this regimen occurs in less than 10 percent of women with incompletely resected stage III disease and less than 5 percent of women with stage IV disease.⁸

After cisplatin emerged as an active drug in epithelial ovarian cancer, over a decade passed before another

From the Department of Medicine, Emory University, Atlanta (W.P.M.); the Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, and the Department of Obstetrics and Gynecology, Cornell University Medical College, New York (W.J.H.); the Gynecologic Oncology Group Statistical Office, Roswell Park Cancer Institute, Buffalo, N.Y. (M.F.B.); the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health Sciences University, Portland (P.R.K.); the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham (E.E.P.); the Division of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis (K.Y.L.); the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, N.C. (D.L.C.-P.); and the Department of Pathology and Area Laboratory Sciences, Walter Reed Army Medical Center, Washington, D.C. (M.D.). Address reprint requests to Dr. McGuire at the GOG Administrative Office, Suite 1945, 1234 Market St., Philadelphia, PA 19107.

Supported by grants from the National Cancer Institute to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

drug was developed that could elicit responses in women with platinum-refractory disease. In 1989, paclitaxel was reported to produce a response rate of 24 percent in women with platinum-resistant ovarian cancer (30 percent overall response rate).⁹ The activity of the drug was confirmed in a less heavily pretreated group of women who received a higher starting dose.¹⁰ The response rate in these women was 37 percent, which made paclitaxel the most active single drug ever evaluated by the Gynecologic Oncology Group in a phase 2 study of ovarian cancer. Subsequently, a phase 1 trial of the paclitaxel and cisplatin combination demonstrated that the two drugs could be safely combined, with the paclitaxel administered first as a 24-hour infusion, followed immediately thereafter by cisplatin.¹¹ The use of paclitaxel in epithelial ovarian cancer has recently been reviewed.^{12,13}

The reproducible activity of paclitaxel as salvage therapy, the ability to combine it easily and safely with cisplatin, and the poor long-term results of standard therapy led the Gynecologic Oncology Group to initiate a prospective, randomized phase 3 trial to compare cisplatin plus paclitaxel with standard therapy in women with incompletely resected stage III or any stage IV ovarian cancer.

METHODS

Women with pathologically verified stage III epithelial ovarian cancer (borderline tumors excluded) who had undergone a surgical procedure and were left with residual disease (>1 cm residual mass) or stage IV disease were eligible for study. They could have clinically measurable or unmeasurable (but able to be evaluated) disease. Other eligibility criteria included having undergone no previous chemotherapy; having given informed consent; having a Gynecologic Oncology Group performance-status score¹⁴ of 0, 1, or 2; and having a white-cell count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level of 2.0 mg per deciliter (177 μ mol per liter) or less, and serum bilirubin and serum aspartate aminotransferase values of no more than twice the upper level of normal for the institution. Patients had to enter the study within six weeks after the surgical procedure, and could have had no previous chemotherapy or radiation for the ovarian cancer nor any previous cancer other than nonmelanoma skin cancer. Women with a history of cardiac arrhythmia or who were currently taking an antiarrhythmic medication were excluded. Pathological material was centrally reviewed to verify that it conformed with acceptable diagnoses. Similarly, each case was reviewed for adequacy of the initial surgical procedure, and one of us reviewed all the operative and pathology reports to assess the volume of tumors before and after surgery as well as to record the findings at second-look surgery.

On entry into the study, the women underwent a review of their history, physical examination, and laboratory procedures. Appropriate imaging procedures to measure the extent of disease were performed before and after every other course of therapy.

The women in the standard-therapy group received cyclophosphamide (750 mg per square meter of body-surface area intravenously) and cisplatin (75 mg per square meter intravenously at the rate of 1 mg per minute) every three weeks for a total of six courses. The women in the experimental-therapy group received paclitaxel (135 mg per square meter intravenously as a 24-hour continuous infusion) and cisplatin (75 mg per square meter intravenously at a rate of 1 mg per minute) every three weeks for a total of six courses. The women assigned to the experimental group were premedicated with dexamethasone (20 mg orally or intravenously 14 and 7 hours before the

start of the paclitaxel infusion). Both diphenhydramine (50 mg) and any histamine H₂ antagonist were administered intravenously 30 minutes before the paclitaxel infusion.

Treatments were randomly assigned by the Statistical Office of the Gynecologic Oncology Group, with equal probability after stratification according to institution and the clinical measurability of disease. Women with clinically measurable disease formed the basis of the determination of the clinical response. Those without measurable disease and those with measurable disease and complete clinical responses at the end of their assigned treatment were required to have a reassessment laparotomy to determine the pathological response.

All adverse effects were graded according to the toxicity criteria of the Gynecologic Oncology Group.¹⁴ The women had to have a white-cell count of at least 3000 per cubic millimeter and a platelet count of at least 100,000 per cubic millimeter before the next course could be administered. Courses were delayed week by week until these counts were achieved. If this delay exceeded three weeks, the woman was withdrawn from the study. No delay in the subsequent courses was allowed for any gastrointestinal toxicity, peripheral neurotoxicity of grade 1 or 2, mild renal toxicity (serum creatinine level of \leq 2 mg per deciliter [177 μ mol per liter] or creatinine clearance of \geq 50 ml per minute), or mild ototoxicity (a reduction of \leq 10 dB in high-frequency discrimination). More severe neurologic, otic, or renal toxic effects that had not resolved by the time of the next scheduled dose required withdrawal of the woman from the study but with continued follow-up. Cardiac toxic effects (except asymptomatic sinus bradycardia) were reported to the study chairman and were considered a cause for discontinuing therapy. A severe allergic reaction (bronchospasm, hypotension, or diffuse urticaria) during the infusion of paclitaxel was an indication for immediate discontinuation of the infusion and withdrawal of the woman from study treatment. Dose reductions of cyclophosphamide or paclitaxel (no reduction in the cisplatin dose was allowed) in subsequent courses were based on nadir counts from the

Table 1. Patients' Characteristics According to Treatment Group.

CHARACTERISTIC	CISPLATIN + CYCLOPHOSPHAMIDE (N = 202)	CISPLATIN + PACLITAXEL (N = 184)
Age (yr)		
Median	60	59
Range	27-80	20-84
	<i>number (percent)</i>	
Gynecologic Oncology Group performance status*		
0	55 (27)	56 (30)
1	109 (54)	97 (53)
2	38 (19)	31 (17)
Cell type		
Serous adenocarcinoma	130 (64)	140 (76)
Endometrioid adenocarcinoma	26 (13)	15 (8)
Mucinous adenocarcinoma	10 (5)	4 (2)
Clear-cell adenocarcinoma	5 (2)	3 (2)
Other	31 (15)	22 (12)
Tumor grade		
1	15 (7)	7 (4)
2	82 (41)	82 (45)
3	105 (52)	93 (51)
Measurable disease		
Yes	116 (57)	100 (54)
No	86 (43)	84 (46)
Stage		
III	129 (64)	123 (67)
IV	73 (36)	61 (33)
Ascites (>100 ml)		
No	29 (14)	21 (11)
Yes	173 (86)	163 (89)

*See Blessing for an explanation of possible scores.¹⁴

previous course. A nadir hematologic toxicity of grade 4 (characterized by a white-cell count of ≤ 1000 per cubic millimeter, an absolute neutrophil count of ≤ 500 per cubic millimeter, or a platelet count of $\leq 25,000$ per cubic millimeter) required the reduction of the cyclophosphamide dose to 500 mg per square meter or of the paclitaxel dose to 110 mg per square meter in the subsequent course, with reescalation in later cycles if nadir counts were not of grade 4.

The clinical response was assessed only in patients with clinically measurable disease, according to previously defined criteria.¹⁵ In the women who underwent reassessment laparotomy, a pathological response was determined and assigned to one of three categories: complete response, partial response with microscopic disease only, and persistent disease. Women who were not surgically reassessed because they either had clinically persistent disease or had progressed before their second-look laparotomy were classified as having persistent disease.

Overall and progression-free survival was measured from the date of randomization. The duration of survival was measured up to the date of death or the date of last contact if the woman was alive at the time of the last contact. The duration of progression-free survival was the minimal amount of time until the onset of clinical progression, death, or the last contact. All eligible cases were included in the analysis of survival and progression-free survival unless otherwise specified. All causes of death were used to calculate survival, and the estimates of the cumulative proportion surviving were based on Kaplan–Meier procedures.¹⁶ The independence of progression-free survival, overall survival, and randomized treatment was assessed with a two-tailed log-rank test,¹⁷ stratified according to the measurability of disease. Linear proportional-hazards analysis was used to provide estimates of relative risk adjusted for other pretreatment factors.¹⁸ Finally, proportional-hazards analysis with an interaction term was used to assess the homogeneity of the treatment effect across prognostic groups.

Only eligible women who received at least one course of treatment were included in the assessment of toxicity. One woman received no treatment. A Kruskal–Wallis rank test¹⁹ adjusted for tied ranks was used to test the independence of the severity of toxicity with regard to the assigned treatment. Pearson's chi-square test²⁰ was used to test the independence of response and treatment. Twelve women, six in each treatment group, could only be partially evaluated and were classified as having no clinical response for the intention-to-treat

Table 2. Number of Courses Completed and Timing, According to Treatment Group.

COURSE	CISPLATIN + CYCLOPHOSPHAMIDE*		CISPLATIN + PACLITAXEL†	
	NO. OF WOMEN TREATED	MEDIAN NO. OF DAYS BETWEEN COURSES	NO. OF WOMEN TREATED	MEDIAN NO. OF DAYS BETWEEN COURSES
1	201‡	—	184	—
2	196	21	175	21
3	187	25	168	21
4	175	27	166	21
5	166	28	163	21
6	158	28	160	21

*The median total dose was 442 mg of cisplatin per square meter and 4176 mg of cyclophosphamide per square meter.

†The median total dose was 441 mg of cisplatin per square meter and 751 mg of paclitaxel per square meter.

‡One woman was not treated.

Table 3. Occurrence of Adverse Effects According to Severity and Treatment Group.*

ADVERSE EFFECT	CISPLATIN + CYCLOPHOSPHAMIDE						CISPLATIN + PACLITAXEL					
	GRADE OF SEVERITY					NO. OF WOMEN	GRADE OF SEVERITY					NO. OF WOMEN
	0	1	2	3	4		0	1	2	3	4	
	<i>percent</i>						<i>percent</i>					
Reduction in white cells or neutrophils†	3	4	9	22	61	197	2	2	4	14	78	179
Reduction in platelets	50	39	7	1	2	198	47	45	4	3	0	180
Anemia	38	17	36	8	0	200	33	15	43	8	<1	182
Gastrointestinal symptoms	29	18	42	8	3	201	28	14	42	12	3	184
Fever†	88	3	8	0	0	201	80	5	11	3	<1	184
Alopecia‡	63	10	27	—	—	201	37	9	54	—	—	184
Renal symptoms	93	3	2	1	<1	201	96	2	1	<1	0	184
Neurologic symptoms	79	13	3	3	1	201	72	15	9	4	0	184
Allergic reaction†	99	0	1	0	0	201	92	2	2	2	2	184

*Results of repeated white-cell or granulocyte counts were not available for nine women, results of repeated platelet counts were not available for seven women, and results of repeated hemoglobin or hematocrit measurements were not available for three women. Because of rounding, not all percentages total 100.

†A Kruskal–Wallis rank test indicated that this effect was more severe in the cisplatin–paclitaxel group ($P \leq 0.05$).

‡Severity of alopecia is graded as 0, 1, or 2.

analysis. Generally, these women received one or two courses of treatment, experienced toxic effects, and then received alternative therapy or refused any further treatment before having any objective response.

RESULTS

Characteristics of the Patients

Four hundred ten women with epithelial ovarian cancer entered the trial. Twenty-four women were ineligible — 3 because their cancer was of an inappropriate stage, 13 because they had the wrong primary tumor, 3 because they had the wrong cell type, 4 because they had a history of cancer, and 1 because she had had the wrong kind of surgery. The remaining 386 eligible women were randomly assigned to either the cisplatin–cyclophosphamide group or the cisplatin–paclitaxel group. The two groups were balanced for several prognostic factors (Table 1).

Dose Delivered and Drug Tolerance

The planned total dose of cisplatin was the same (450 mg per square meter) for both treatment groups. The 25th, 50th, and 75th percentiles of the actual cisplatin dose delivered were 410, 442, and 450 mg per square meter, respectively, for the women in the cisplatin–cyclophosphamide group and 425, 441, and 449 mg per square meter, respectively, for those in the cisplatin–paclitaxel group. There was no difference between the groups in the total delivered dose of cisplatin.

Table 2 shows the number of women treated at each cycle of treatment and the interval between consecutive cycles. More women completed the paclitaxel-based regimen (160 of 184 [87 percent]) than the standard (cisplatin–cyclophosphamide) regimen (158 of 202 [78

percent]). Twenty-three women (11 percent) in the standard-regimen group and nine (5 percent) in the paclitaxel group did not complete all six cycles of therapy because of disease progression or death. Twenty-one women in the standard-regimen group (10 percent) and 15 in the paclitaxel group (8 percent) did not complete six cycles of therapy, either because of toxicity or because they declined to do so.

Toxicity

The frequency of adverse effects for the 385 eligible women who received at least one course of treatment is shown in Table 3. The severity of neutropenia, febrile neutropenia, alopecia, and peripheral neurotoxicity was significantly different in the two treatment groups ($P \leq 0.05$), with more toxicity in the cisplatin–paclitaxel group. Although neutropenia of grade 3 or 4 developed in the majority of women in the cisplatin–paclitaxel group, the incidence of febrile neutropenia was low and was consistent with the brevity of paclitaxel-induced myelosuppression. Peripheral neurotoxicity was more common in the paclitaxel group but overall was very mild. In 10 women death was at least partly attributed to treatment — 6 in the cisplatin–cyclophosphamide group and 4 in the cisplatin–paclitaxel group. Since bradyarrhythmias with atrioventricular block and ventricular irritability have been reported in patients receiving paclitaxel therapy,²¹ the initial phase of this study required all women in the cisplatin–paclitaxel group to undergo cardiac monitoring. However, only seven women in the paclitaxel group had cardiac episodes of grade 2 or higher, such as first-degree heart block or ischemic events without other symptoms and without infarction. Therefore, the requirement of cardiac monitoring was suspended near the end of the study.

Response

Response was assessed in the 216 women who entered the study with clinically measurable disease (Table 4). The overall response rate in the cisplatin–cyclophosphamide group was 60 percent, and it was 73 percent in the cisplatin–paclitaxel group. Complete clinical responses were more frequent among women treated with cisplatin and paclitaxel (51 percent) than

Table 4. Clinical Response According to Treatment Group.

CLINICAL RESPONSE	CISPLATIN + CYCLOPHOSPHAMIDE (N = 116)	CISPLATIN + PACLITAXEL (N = 100)
	number (percent)*	
Complete	36 (31)	51 (51)
Partial	34 (29)	22 (22)
None	46 (40)	27 (27)

*Values are the numbers and percentages of women with clinically measurable disease.

Table 5. Results of Reassessment Laparotomy According to Treatment Group.

REASSESSMENT RESULT	CISPLATIN + CYCLOPHOSPHAMIDE*	CISPLATIN + PACLITAXEL†
Negative	35 (20)	42 (26)
Microscopically positive	7 (4)	23 (14)
Persistent disease‡	136 (76)	95 (59)
Procedure contraindicated or refused	24	24
Total	202	184

*Values in parentheses are percentages of evaluated cases. Percentages do not include the 24 women in this treatment group who declined second-look surgery.

†Percentages do not sum to 100 because of rounding.

‡This category includes clinically persistent and gross surgical disease.

among those treated with cisplatin and cyclophosphamide (31 percent) ($P = 0.01$, χ^2_2).

Women who had complete clinical responses or who did not have measurable disease on entering the study and had not had interval progression were required by the protocol to undergo a reassessment laparotomy. Of the 386 women, 48 (24 in each treatment group) did not undergo the procedure because of refusal or contraindication (Table 5). There was no significant difference in the proportion of negative reassessment laparotomies between the two treatment groups (20 percent vs. 26 percent).

Figures 1 and 2 show the progression-free and overall survival curves for all the eligible women. The median duration of follow-up for women alive at last contact was 37 months (range, 5 to 56). There was a statistically significant difference between the treatment groups in both these comparisons. The median progression-free survival in the cisplatin–cyclophosphamide group was 13 months (95 percent confidence interval, 11 to 15); in the cisplatin–paclitaxel group it was 18 months (95 percent confidence interval, 16 to 21) (relative risk, 0.7; 95 percent confidence interval, 0.5 to 0.8; $P < 0.001$). The median survival of women treated with cisplatin and cyclophosphamide was 24 months (95 percent confidence interval, 21 to 30), and for women treated with cisplatin and paclitaxel it was 38 months (95 percent confidence interval, 32 to 44) (relative risk, 0.6; 95 percent confidence interval, 0.5 to 0.8; $P < 0.001$). Including the 24 women who were deemed ineligible for this study did not appreciably alter these results.

The overall survival of women with and without clinically measurable disease in each treatment group and the overall survival according to the stage of disease were also assessed (data not shown). There was no evidence that the combination of cisplatin and paclitaxel was less effective than cisplatin and cyclophosphamide within those prognostic groupings.

Previous studies conducted by the Gynecologic Oncology Group that included women with incompletely resected stage III or IV disease suggested that those


with either mucinous or clear-cell adenocarcinoma tended to have a poor prognosis.²² Removal of such cases from the comparison of progression-free survival and overall survival did not alter the results.

DISCUSSION

The results of this trial provide strong evidence that the cisplatin–paclitaxel regimen we used is more effective than cisplatin and cyclophosphamide for women with advanced ovarian cancer. There was a good balance of known prognostic factors between the two treatment groups, and random sampling was unlikely to explain the differences in survival, progression-free survival, and complete response rate.


The results we obtained are similar to those of the predecessor to this trial — a study that included a similar sample of women who were treated with similar doses of cisplatin and paclitaxel.²³ It appears that the relative benefit of paclitaxel in our trial was not due to a poorer-than-anticipated outcome among the women receiving standard therapy. There is no evidence that the benefit of cisplatin and paclitaxel was limited to women with measurable disease or to those with stage III disease. The toxicity of the drugs was clinically manageable.

When an active new drug enters clinical use, its effect on survival may be blunted because of the crossover of patients from the old standard to the new drug. There may be a similar but less profound effect on progression-free survival when crossover occurs before clinical progression — for example, after a positive reassessment laparotomy. Such a situation occurred when cisplatin, already commercially available, was incorporated into primary tumor therapy.³ This may explain why the effect on survival was not more profound when



Treatment	No. Progression-free	No. with Treatment Failure	Total	Median Progression-free Survival (mo)
— Cisplatin + cyclophosphamide	28	174	202	13
- - - Cisplatin + paclitaxel	45	139	184	18

Figure 1. Progression-free Survival, According to Treatment Group.



Treatment	No. Alive	No. Dead	Total	Median Survival (mo)
— Cisplatin + cyclophosphamide	65	137	202	24
- - - Cisplatin + paclitaxel	86	98	184	38

Figure 2. Survival According to Treatment Group.

cisplatin was first incorporated into primary tumor therapy. Crossover may have affected our trial, but to a smaller degree than usual, because paclitaxel was in limited supply during the early accrual phase of the study and the women in the cisplatin–cyclophosphamide group were often prevented from receiving paclitaxel until after they had received third-line or fourth-line therapy.

The results of this study are encouraging, but we are concerned that variants of the cisplatin–paclitaxel regimen are being adopted without proper evaluation. Some clinicians have substituted carboplatin for cisplatin, even though the carboplatin–paclitaxel combination is still in a phase I evaluation.²⁴

Of even greater concern to us is the reduction in the length of paclitaxel infusion to three hours or less. This practice is based largely on a trial of paclitaxel alone as second- and third-line therapy that showed similar efficacy for 3-hour and 24-hour infusions and less hematologic toxicity with the shorter infusion.²⁵ This approach may be preferred by patients and may have financial advantages, but the efficacy of a three-hour infusion of paclitaxel has not been verified. Our concern about this is pertinent because in vitro data show that the duration of exposure to paclitaxel is much more important than the peak level of exposure.²⁶

APPENDIX

The following Gynecologic Oncology Group institutions participated in this study: Oregon Health Sciences Center, Johns Hopkins Oncology Center, University of Alabama at Birmingham, Duke University Medical Center, Colorado Foundation for Medical Care, Bowman Gray School of Medicine of Wake Forest University, Temple University Health Science Center Hospital, University of Minnesota Medical School, University of Mississippi Medical Center, University of California Medical Center at Irvine, Walter Reed Army Medical Center, University of Iowa Hospitals and Clinics, University of Kentucky, Pennsylvania Hospital, Washington University School of Medicine, Cooper Hospital University Medical Center, Cleveland Clinic

Foundation, University of Texas, M.D. Anderson Cancer Center, Georgetown University Hospital, University of Rochester Medical Center, University of Southern California Medical Center at Los Angeles, Tufts–New England Medical Center, Columbus Cancer Council, University of Cincinnati College of Medicine, Albany Medical College of Union University, Illinois Cancer Council, Wayne State University School of Medicine, Milton S. Hershey School of Medicine of Pennsylvania State University, University of California Medical Center at Los Angeles, University of North Carolina School of Medicine, University of Massachusetts Medical Center, Medical University of South Carolina, Women's Cancer Center of Northern California, University of Oklahoma Health Science Center, Fox Chase Cancer Center, University of Miami School of Medicine, University of Texas Health Science Center at Dallas, State University of New York Downstate Medical Center, Eastern Virginia Medical School, and State University of New York at Stony Brook.

REFERENCES

- Williams CJ, Mead GM, Macbeth FR, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. *J Clin Oncol* 1985;3:1455-62.
- Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. *Lancet* 1984;2:594-600.
- Omura GA, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study. *Cancer* 1986;57:1725-30.
- Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. *BMJ* 1991;303:884-93.
- Thigpen JT, Blessing JA, Vance RB, Lambuth BW. Chemotherapy in ovarian carcinoma: present role and future prospects. *Semin Oncol* 1989;16:58-65.
- GICOG (Gruppo Interregionale Cooperativo Oncologico Gynecologica). Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. *Gynecol Oncol* 1992;45:115-7.
- Williams CJ, Stewart L, Parmar M, Guthrie D. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma: the Advanced Ovarian Cancer Trialists Group. *Semin Oncol* 1992;19:Suppl 2:120-8.
- Sutton GP, Stehman FB, Einhorn HL, Roth LM, Blessing JA, Ehrlich CE. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. *J Clin Oncol* 1989;7:223-9.
- McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. *Ann Intern Med* 1989;111:273-9.
- Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. *J Clin Oncol* 1994;12:1748-53.
- Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. *J Clin Oncol* 1991;9:1691-703.
- McGuire WP. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. *Gynecol Oncol* 1993;51:78-85.
- Rowinsky EK, Donehower RC. Paclitaxel (Taxol). *N Engl J Med* 1995;332:1004-14.
- Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, ed. *Chemotherapy of gynecologic cancer*. 2nd ed. New York: Wiley-Liss, 1990:63-97.
- WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457-81.
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep* 1966;50:163-70.
- Cox DR. Regression models and life-tables. *J R Stat Soc [B]* 1972;34:187-220.
- Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. *J Am Stat Assoc* 1952;47:583-621.
- Agresti A. *Categorical data analysis*. New York: John Wiley, 1990.
- Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. *J Clin Oncol* 1991;9:1704-12.
- Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. *J Clin Oncol* 1991;9:1138-50.
- McGuire WP, Hoskins WJ, Brady MF, et al. An assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 1995;13:1589-99.
- Bookman MA, McGuire WP, Kilpatrick E, et al. Phase I Gynecologic Oncology Group (GOG) study of 3-h and 24-h paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (OvCA). *J Clin Oncol* (in press).
- Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. *J Clin Oncol* 1994;12:2654-66.
- Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. *Br J Cancer* 1993;68:1104-9.

IMAGES IN CLINICAL MEDICINE

Images in Clinical Medicine, a weekly *Journal* feature, presents clinically important visual images, emphasizing those a doctor might encounter in an average day at the office, the emergency department, or the hospital. If you have an original unpublished, high-quality color or black-and-white photograph representing such a typical image that you would like considered for publication, send it with a descriptive legend to Kim Eagle, M.D., University of Michigan Medical Center, Division of Cardiology, 3910 Taubman Center, Box 0366, 1500 East Medical Center Drive, Ann Arbor, MI 48109. For details about the size and labeling of the photographs, the requirements for the legend, and authorship, please contact Dr. Eagle at 313-936-5275 (phone) or 313-936-5256 (fax), or the *New England Journal of Medicine* at images@edit.nejm.org (e-mail).

CORRECTION

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer . On page 1, in the Results paragraph of the Abstract, the fourth sentence should have read, "Among 216 women with measurable disease, 51 percent of the cisplatin–paclitaxel group had a complete response to therapy and 22 percent a partial response, whereas 31 percent of the cisplatin–cyclophosphamide group had a complete response and 29 percent a partial response ($P = 0.01$, $\chi^2_2 = 8.97$)."

CORRECTION

Chemotherapy for Ovarian Cancer

To the Editor: As reported by McGuire et al. (Jan. 4 issue),¹ the results of the Gynecologic Oncology Group's phase 3 trial comparing paclitaxel plus cisplatin with cyclophosphamide plus cisplatin in women with ovarian cancer are exciting and encouraging. However, the data from this trial need to be interpreted with caution, for a number of reasons.

First, there is increasing evidence that the patients in the control group may not have received the best available platinum-based treatment. McGuire et al. state, "It appears that the relative benefit of paclitaxel in our trial was not due to a poorer-than-anticipated outcome" in the control group. To support their statement, the authors refer to a predecessor to their trial, which had similar results. This previous Gynecologic Oncology Group trial² compared a standard-dose regimen of cyclophosphamide and cisplatin with an intensive-dose regimen (and did not involve "similar doses of cisplatin and paclitaxel" — this is clearly an error). In the intensive-dose regimen, the dose intensity of both cisplatin and cyclophosphamide was doubled, but the total dose of the two drugs was identical in each group.

A trial by Kaye et al.,³ however, which also compared two cyclophosphamide and cisplatin regimens, one of which involved a doubling of both the dose intensity and the total dose of cisplatin, has shown a survival benefit associated with the regimen involving a higher total dose of cisplatin. There is also strong evidence from meta-analyses that the addition of doxorubicin to cyclophosphamide and cisplatin is a more effective treatment than cyclophosphamide and cisplatin alone.^{4,5}

Second, McGuire et al. estimated that paclitaxel plus cisplatin improved the median survival by 14 months. Nevertheless, there is still uncertainty about the true effect. The approximate 95 percent confidence interval for the range of effects that are still plausible is six months to two years. A difference in survival of two years would be exciting, a difference of six months less so.

Finally, the improvement in median progression-free survival was less than half the observed improvement in median survival. Such an apparent discrepancy would not have been expected and raises the question whether there may be an element of chance associated with the much larger observed difference in overall survival.

Despite the very encouraging results of this trial, there is an urgent need for further large trials comparing the combination of paclitaxel and platinum with the best current standard treatment available. The Third International Collaborative Ovarian Neoplasm Study, which has a maximal accrual target of 1000 patients and 265 patients enrolled to date, is one such trial, and it involves a broader range of women with ovarian cancer.

Mahesh K.B. Parmar, D.Phil.

Josie Sandercock, B.A.

Medical Research Council Cancer Trials Office
Cambridge CB2 2BW, United Kingdom

References

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996;334:1-6.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 1995;13:1589-1599.
3. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. *Lancet* 1992;340:329-333.
4. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. *J Clin Oncol* 1991;9:1668-1674.
5. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. *BMJ* 1991;303:884-893.

To the Editor: The article by McGuire et al. on chemotherapy for suboptimally debulked advanced ovarian cancer contains ambiguities that need clarification, although we agree with the overall conclusions.

The imbalance of prognostic factors in the two treatment groups (12 percent fewer patients with serous adenocarcinoma and almost double the proportion of grade 1 tumors in the cisplatin-cyclophosphamide group), the lack of mention of differences in outcome among the participating centers (one of the two variables stratified in the randomization process), and the lack of adjustment for imbalances in prognostic factors in the analysis of progression-free and overall survival are some of the technical points that require clarification. The proportion of ineligible patients (5.9 percent) was low, but no mention is made of the distribution of such patients in the two groups or the reasons for their ineligibility (the wrong primary tumor [in 13 patients] and the wrong cell type [in 3] are not clear enough reasons), which is a matter of concern, since there were 9 percent fewer patients in the cisplatin-paclitaxel group than in the cisplatin-cyclophosphamide group.

The fact that 97 percent of the patients had been enrolled by November 1992,¹ together with the follow-up range reported (5 to 56 months), shows that the data are at least 30 months old, without any update since mid-1993. The report does not mention the starting and ending dates for enrollment or the rate of enrollment, the cutoff date

for the last collection of data is not stated, and the survival curves show no denominators for patients at risk over time. The results of the trial will not change, but the overall shape of the curves and level of significance may change.

The most important issue is that the 5-month difference in the median time to the progression of disease is only about one third the difference in median overall survival (14 months), a counterintuitive and rare finding in clinical trials involving patients with advanced malignant solid tumors. Such a result is probably due to differences in second-line therapy in the two groups. Patients in the cisplatin-paclitaxel group with a recurrence or progression of disease appear to have been treated further with alkylating agents, but the authors do not indicate whether they were treated again with paclitaxel. The authors state that patients in the cisplatin-cyclophosphamide group did not receive paclitaxel as second-line treatment, or received it only very late in the course of the disease, because a limited supply of paclitaxel prevented a crossover study. Either the crossover was specifically not allowed, or there is an ethical problem, since the supply of paclitaxel during the period of the investigation was adequate for its distribution as salvage therapy on a compassionate-use basis to at least 1819 patients with ovarian cancer in the United States.² This point is worrisome, because the end points of the trial are not clearly stated in the article. The difference in survival between the two groups may thus be due solely to the fact that the patients randomly assigned to the paclitaxel-cisplatin group received three active drugs during their illness, whereas most patients in the control group received only two active drugs.

Since second-line therapeutic choices in ovarian cancer result in good palliation and the prolongation of life, differences in overall survival are likely to be significantly influenced by second-line treatment. If McGuire et al. denied such treatment to one or both groups of patients, we believe this approach is questionable as an ethical therapeutic design.

Esteban Cvitkovic, M.D.
Jean-Louis Misset, M.D.
Hôpital Paul Brousse
94804 Villejuif, France

References

1. McGuire WP, Hoskins WJ, Brady MF, et al. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). *Prog Proc Am Soc Clin Oncol* 1993;12:255. abstract.
2. Trimble EH, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. *J Clin Oncol* 1993;11:2405-2410.

To the Editor: The group of patients treated with paclitaxel and cis-

platin had little or no delay between consecutive cycles of treatment (21 days). However, in the group treated with cyclophosphamide and cisplatin, which had less severe leukopenia, there were delays between cycles (27 days after the fourth cycle). This suggests that there was a reduction in the dose intensity of cisplatin in the standard-treatment group from the initial planned dose of 25 mg per square meter of body-surface area per week to 18.7 mg per square meter per week after the fourth cycle. Moreover, the dose-reduction schedule in the protocol recommends a 33 percent decrease in the total dose of cyclophosphamide, as compared with a 15.6 percent decrease in the total dose of paclitaxel. This difference, along with the lower dose intensity of cisplatin in the standard-treatment group, may explain the difference in the outcome.

It is also important that the two groups of patients did not differ in terms of the number of complete responses confirmed by second-look operations. We think a longer follow-up is needed to determine whether the difference in survival is maintained.

This limitation of the study, the high cost of the treatment, and the difficulties of the schedule proposed by the authors (a 24-hour infusion, which suggests an added cost) lead us to conclude that paclitaxel and cisplatin should not be adopted in routine clinical practice until more studies have confirmed that this regimen increases the cure rate or long-term progression-free survival.

Angel J. Lacave, M.D.
Ignacio Peláez, M.D.
Isabel Palacio, M.D.
Hospital General de Asturias
33006 Oviedo, Spain

The authors reply:

To the Editor: We agree that clinical trials in women with advanced ovarian carcinoma that focus only on survival can be misleading. Since it is not clear how tumor debulking during reassessment surgery and the timing of salvage chemotherapy affect survival, we are continuing to assess clinical responses in patients with measurable disease.

Parmar and Sandercock and Lacave et al. suggest that the benefit we found in overall and progression-free survival among patients treated with cisplatin and paclitaxel is due to an inappropriate standard treatment. Parmar and Sandercock suggest that we should have used a more intensive regimen of cisplatin, whereas Lacave et al. note that the toxic effects of the standard regimen required delays between courses of treatment and therefore resulted in a diminished dose intensity. The doses in our study were a reasonable compromise between intensive regimens of cisplatin and cyclophosphamide, which cause substantial toxic effects, and less intensive regimens, which prolong the treatment in order to achieve the total doses planned.¹

The results of a meta-analysis suggest that adding doxorubicin to regimens based on an alkylating agent or platinum may decrease the death rate by 15 percent.² Parmar and Sandercock note that this result is similar to an estimate from a meta-analysis of randomized trials

comparing platinum and nonplatinum regimens.³ Most of these trials, however, did not restrict the use of platinum in salvage therapy. Any advantage due to platinum given in the initial treatment was probably obscured, since the survival comparisons reflect early versus late treatment with platinum.³ Because the evidence for doxorubicin is not compelling, considering it equivalent to platinum overstates its benefit.

Cvitkovic and Misset suggest that the observed survival benefit associated with paclitaxel is due to the 3 percent difference in grade 1 tumors. This small difference, however, favors the cisplatin–cyclophosphamide regimen rather than the cisplatin–paclitaxel regimen. In addition, previous studies have indicated that with the exception of the clear-cell and mucinous types, the cell type is not an important prognostic factor in women with suboptimally debulked ovarian cancer.

Although the manuscript we submitted indicated that patients were enrolled in this study between April 1990 and March 1992, this information was deleted in the editorial process. The results presented summarize the data on survival as of April 1995. The tick marks in Figure 1 and Figure 2 of the article indicate the censored survival times. The follow-up of these patients is ongoing.

W.P. McGuire, M.D.
Emory University
Atlanta, GA 30322

W.J. Hoskins, M.D.
Memorial Sloan-Kettering Cancer Center
New York, NY 10021

M.F. Brady, B.S.
Roswell Park Cancer Institute
Buffalo, NY 14263

References

1. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 1995;13:1589-1599.
2. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. *J Clin Oncol* 1995;13:726-732.
3. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. *BMJ* 1991;303:884-893.